Health Care/Hospital

Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Oral Agent Designed to Address High Incidence of Relapse in DLBCL Population INDIANAPOLIS, March 27 /Xinhua-PRNewswire/ -- Eli Lilly and Company announced to-day that the European Medicines Agency (EMEA) has granted enzastaurin, an in-vestigational, multi-targeted, oral, cancer agent, orpha...

2007-03-27 08:39 749

WuXi PharmaTech Installs Supercritical Fluid Chromatography System

SHANGHAI, China, March 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech, China's leading provider of pharmaceutical R&D outsourcing services announced today that it has purchased and successfully brought online a Berger Supercritical Fluid Chromatography (SFC) MultiGram(R)III preparative system. ...

2007-03-26 21:53 1525

China Pharma Holdings, Inc. Announces Conference Call to Discuss Fourth Quarter and Year-End 2006 Results

HAIKOU CITY, Hainan Province, China, March 26 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) today announced that the Company will host a conference call at 09:00 am EST on Thursday, March 29, 2007, to discuss results for the fourth quart...

2007-03-26 20:00 747

World Stop TB Day - 24 March 2007

Message From Dr Henk Bekedam, WHO Representative in China BEIJING, March 23 /Xinhua-PRNewswire/ -- World Stop Tuberculosis (TB) Day is an important occasion and this year's theme - Drug-resistant TB: Treat it. Prevent it - is a vital reminder of the challenges that remain in China's fight ...

2007-03-23 15:59 689

Lilly Announces Additional $50 Million Investment in Global Tuberculosis Partnership

Funding enables partnership to continue critical battle against MDR-TB; Reinvestment brings Lilly's total commitment to $120 million for long-term, sustainable program NEW YORK, March 22 /Xinhua-PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $...

2007-03-22 12:01 793

Potentia Pharmaceuticals Announces Initiation of Phase I Clinical Trials to Evaluate its Lead Compound for Age-Related Macular Degeneration

-- POT-4 is the First Complement Inhibitor for Age-related Macular Degeneration to Enter Clinical Phase of Development LOUISVILLE, Ky., March 20 /Xinhua-PRNewswire/ -- Potentia Pharmaceuticals, Inc. announced today that it is entering the clinical phase of development for POT-4, its...

2007-03-20 16:00 785

REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis

The Reduction of Atherothrombosis for Continued Health (REACH) Registry 1-Year Results PARIS, March 20 /Xinhua-PRNewswire/ -- The REACH Registry 1-year results paper published today in the Journal of the American Medical Association (JAMA) show that outpatients with atherothrombosis have a s...

2007-03-20 22:00 816

SEROQUEL(R) Sustained Release Schizophrenia Data Presented at ECP Congress in Madrid

LONDON, March 19 /Xinhua-PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced SEROQUEL(R) sustained release formulation (quetiapine fumarate sustained release) clinical trial data presented at the European Congress of Psychiatry (ECP) in Madrid. The data demonstrated that the SEROQUEL(R) ...

2007-03-19 09:02 752

Pharmaxis Reports Phase II Results for Aridol in COPD

SYDNEY, Australia, March 14 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the results from its Phase II trial for Aridol in subjects with Chronic Obstructive Pulmonary Disease (COPD), a respiratory disease affecting over 30 million p...

2007-03-14 21:00 654

Mindray Medical International Announces Fourth Quarter and Full Year 2006 Results

Rapid International Expansion Drives Record Revenues Company Ends Year with Strong Debt-free Balance Sheet; Declares Cash Dividend of US$0.15 Per Share SHENZHEN, China, March 12 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR) today announced its selecte...

2007-03-12 20:13 742

Protection From Osteoporosis - Bone is Living Tissue

Protection From Osteoporosis - Bone is Living Tissue BASEL, Switzerland, March. 8 /Xinhua-PRNewswire/ -- In Europe, a bone breaks every 30 seconds due to osteoporosis. Each year, nearly 1.5 million Americans over 50 suffer fractures caused by this bone disease. Bone is a living tis...

2007-03-08 12:17 833

China Biopharmaceuticals Holdings' Subsidiary Enshi Pharmaceuticals Wins Two Industry Awards

Our Hepatitis drug, Ganbifu, Named as One of China's 2006 "Top Ten Most Popular Hepatic Drugs" Enshi's General Manager, Peixiang Cong, Honored as One of China's 2006 "Outstanding Managers for Brand Promotion" BEIJING, March 7 /Xinhua-PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdin...

2007-03-07 22:00 668

China Sky One Medical Announces Three New Diagnostic Kits Have Passed National Final Inspection

HARBIN, China, March 6 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (OTC Bulletin Board: CSKI), one of the leading producers and distributors for external-Chinese medicine in China, has announced that the AMI Diagnostic Kit, Human Urinary Albumin Elisa Kit and Early Pregnancy...

2007-03-06 21:00 760

Sinovac Provides Update on Study of Third Dose of Its Pandemic Influenza Vaccine

BEIJING, March 6 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced an update for the study evaluating the third dose of its vaccine against the H5N1 dose of pandemic influenza. In order to test the immune...

2007-03-06 21:00 1062

Natural Health Trends Corp. Stockholders Filed a Schedule 13-D/A

DALLAS, Texas, March 2 /Xinhua-PRNewswire-FirstCall/ -- Mr. Rudy Ru and a group of stockholders of Natural Health Trends Corp (the "company"; Nasdaq: BHIP), an international direct selling company, announced today that they filed an amended schedule 13-D/A on February 27, 2007. The Ite...

2007-03-02 16:42 996

Phase II Cystic Fibrosis Study Closes Enrollment

SYDNEY, Australia, March 1 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) announced on Feb 23 that a Phase II clinical trial of Bronchitol in children with cystic fibrosis has closed its enrollment phase. The study is an independent investigator-initiated study be...

2007-03-01 21:35 724

Mindray to Present at Lehman Brothers 10th Annual Global Healthcare Conference

SHENZHEN, March 1 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices in China with a rapidly growing international presence, today announced that Mr. Xu Hang, Mindray's Chairman and Co-Chief Exe...

2007-03-01 21:00 627

Fourth Phase III Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients With Advanced Lung Cancer

A Phase III international, parallel group, randomised, double-blind study of vandetanib in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC) after failure of first line anti-cancer therapy -- For Non-US Healthcare Professional Press Only -- ALDERLEY PARK, Ches...

2007-02-26 22:00 881

ScinoPharm's 2006 Revenue and Net Income at Record High

TAINAN, Taiwan, Feb. 26 /Xinhua-PRNewswire/ -- Active pharmaceutical ingredient (API) specialist ScinoPharm reported a 43% rise in its annual revenue to US$44.9 million for 2006, and a positive net income for the first year since the company's inception. Sales on selected anti-oncologics such...

2007-02-26 21:00 734

Elsevier Announces Its Point-Of-Care Medical Information to Be Offered as Part of Chinese Electronic Health Record

Partnership with ChinaMedCom is a First of its Kind Between a U.S. Publisher and a Chinese Healthcare Information Technology Company and Puts FirstCONSULT Evidence-based Clinical Information Directly into Electronic Health Records for Hospitals in China NEW ORLEANS, Feb. 26 /Xinhua-PRNews...

2007-02-26 21:00 891
1 ... 517518519520521522523 ... 526